These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20385901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J.
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Sorensen PS, Bertolotto A.
    Neurology; 2007 Oct 09; 69(15):1552; author reply 1553. PubMed ID: 17923618
    [No Abstract] [Full Text] [Related]

  • 6. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H.
    Neurology; 2007 Oct 09; 69(15):1553-4; author reply 1555. PubMed ID: 17923619
    [No Abstract] [Full Text] [Related]

  • 7. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
    Giovannoni G, Goodman A.
    Neurology; 2005 Jul 12; 65(1):6-8. PubMed ID: 16009876
    [No Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 9. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S, McFarland HF.
    Baillieres Clin Neurol; 1997 Oct 12; 6(3):467-80. PubMed ID: 10101584
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
    J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.